Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Peter Henry Schur, M.D.

Co-Author

This page shows the publications co-authored by Peter Schur and Karen Costenbader.
Connection Strength

2.338
  1. We need better classification and terminology for "people at high risk of or in the process of developing lupus". Arthritis Care Res (Hoboken). 2015 May; 67(5):593-6.
    View in: PubMed
    Score: 0.616
  2. Discordance between erythrocyte sedimentation rate and C-reactive protein measurements: clinical significance. Clin Exp Rheumatol. 2007 Sep-Oct; 25(5):746-9.
    View in: PubMed
    Score: 0.362
  3. Different indirect immunofluorescence ANA substrate performance in a diagnostic setting of patients with SLE and related disorders: retrospective review and analysis. Lupus Sci Med. 2020 11; 7(1).
    View in: PubMed
    Score: 0.226
  4. Development of SLE among "potential SLE" patients seen in consultation: long-term follow-up. Int J Clin Pract. 2014 Dec; 68(12):1508-13.
    View in: PubMed
    Score: 0.144
  5. Clinical manifestations and survival among adults with (SLE) according to age at diagnosis. Lupus. 2014 Jul; 23(8):778-84.
    View in: PubMed
    Score: 0.142
  6. Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus. J Am Acad Dermatol. 2013 Jul; 69(1):19-24.
    View in: PubMed
    Score: 0.133
  7. Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis Rheum. 2010 May; 62(5):1431-7.
    View in: PubMed
    Score: 0.109
  8. Development and initial validation of a self-assessed lupus organ damage instrument. Arthritis Care Res (Hoboken). 2010 Apr; 62(4):559-68.
    View in: PubMed
    Score: 0.108
  9. Quantifying anti-cyclic citrullinated peptide titres: clinical utility and association with tobacco exposure in patients with rheumatoid arthritis. Ann Rheum Dis. 2009 Feb; 68(2):201-8.
    View in: PubMed
    Score: 0.094
  10. C-reactive protein, anti-C-reactive protein antibodies and clinical atherosclerosis. Vasc Med. 2008 Feb; 13(1):25-8.
    View in: PubMed
    Score: 0.093
  11. Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis. Ann Rheum Dis. 2008 Nov; 67(11):1557-61.
    View in: PubMed
    Score: 0.093
  12. Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. Arthritis Rheum. 2005 Oct 15; 53(5):718-23.
    View in: PubMed
    Score: 0.080
  13. Elevated Anti-Citrullinated Protein Antibodies Prior to Rheumatoid Arthritis Diagnosis and Risks for Chronic Obstructive Pulmonary Disease or Asthma. Arthritis Care Res (Hoboken). 2021 04; 73(4):498-509.
    View in: PubMed
    Score: 0.058
  14. Asthma and elevation of anti-citrullinated protein antibodies prior to the onset of rheumatoid arthritis. Arthritis Res Ther. 2019 11 21; 21(1):246.
    View in: PubMed
    Score: 0.053
  15. Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis. J Rheumatol. 2009 Apr; 36(4):706-11.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.